Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351267 | 0.86 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL2351999 | 0.84 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL2353756 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL2351484 | 0.81 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL2320143 | 0.80 | PTGS2 (0.52) | PTGS2PTGS1 | |
| SCHEMBL1162420 | 0.79 | PTGS2 (0.46) | PTGS2PTGS1 | |
| SCHEMBL1961471 | 0.78 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL10015964 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL3617636 | 0.74 | PTGS2 (0.50) | PTGS2PTGS1KDM4EALDH1A1MAPT | |
| SCHEMBL7838788 | 0.73 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144674-A1 | PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2077997-A1 | PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008049585-A1 | PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-05-02 | — | — | WO | disclosed |
| EP-1916240-A1 | Pyridazine derivatives | Syngeta Participations AG (CH) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144674-A1 | PYRIDAZINE DERIVATIVES | C3AR1, C1S, CBR3 | PTGS2 1590/4885PTGS1 1970/4885PTGER3 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.